ANI Pharmaceuticals, Inc.
92.23-1.06 (-1.14%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · ANIP · USD
Key Stats
Market Cap
2.06BP/E (TTM)
-Basic EPS (TTM)
-0.69Dividend Yield
0%Recent Filings
8-K
Preferred stock fully converted
ANI Pharmaceuticals fully converted its outstanding Series A Convertible Preferred Stock into common shares on September 26, 2025, eliminating all preferred obligations. Ampersand, the holder, first converted 5,000 shares into 120,580 common shares on August 14, 2025, at $41.4662 per share; the remaining 20,000 shares became 482,320 common shares after meeting the mandatory trigger of the stock's volume-weighted average price exceeding 170% of the conversion price over 20 of 30 trading days. This simplifies the capital structure, ending 6.50% cumulative dividends tied to the original $25 million investment from the 2021 Novitium Pharma acquisition. No preferred shares remain.
8-K
ANI unveils strong Q2 results
ANI Pharmaceuticals' CEO Nikhil Lalwani presents at the H.C. Wainwright Global Investment Conference on September 8, 2025, and Morgan Stanley Global Healthcare Conference on September 9, unveiling an updated investor deck. It spotlights robust Q2 2025 results, with total revenues hitting $211M—up 53% year-over-year—fueled by Cortrophin Gel's $82M surge and 98% Rare Disease growth. Guidance holds steady: $818-843M net revenue and $213-223M adjusted non-GAAP EBITDA for 2025. Supply chain risks linger from single-source manufacturing.
8-K
Record Q2 revenues, raised guidance
ANI Pharmaceuticals crushed Q2 2025 with record net revenues of $211.4 million, up 53.1% year-over-year, fueled by Cortrophin Gel's 66.0% surge to $81.6 million and Generics' 22.1% rise to $90.3 million. Rare Disease now dominates, hitting $104.0 million amid strong new patient starts and pre-filled syringe uptake. ANI raised 2025 guidance to $818–$843 million in revenues, $213–$223 million adjusted EBITDA. Momentum builds, but acquisition debt lingers.
10-Q
Q2 FY2025 results
ANI Pharmaceuticals posted solid Q2 results, with net revenues jumping 53% year-over-year to $211.4 million, fueled by Cortrophin Gel's 66% surge to $81.6 million on ACTH market expansion and share gains, plus $22.3 million from the newly acquired ILUVIEN and YUTIQ retina franchise. Generics added 22% growth to $90.3 million, driven by launches like Prucalopride (now facing post-exclusivity competition) and volume ramps in estradiol and ketoconazole, while gross margins improved to 64.7% from a favorable product mix. Operating income rose to $13.9 million (up from $5.2 million), with diluted EPS at $0.36 versus a $0.14 loss last year; EPS aligns with 20.3 million diluted shares, no anti-dilution noted. Cash swelled to $217.8 million after $110.8 million in operating flows, supporting $325 million term debt (6.9% rate, due 2029) and $316 million convertibles (2.25%, due 2029) with $75 million revolver available; the Alimera deal closed September 2024 for $418.8 million (mostly cash, $8.3 million CVRs), adding $400 million in 12-year intangibles and $32.3 million goodwill. Free cash flow hit $104.3 million (derived: ops cash minus $6.5 million capex). Patent expirations loom as a key risk, potentially eroding branded sales.
8-K
Jury denies ANI royalty damages
ANI Pharmaceuticals lost a key Delaware jury verdict on July 29, 2025, in its royalty dispute with CG Oncology over cretostimogene sales under a 2010 agreement. The jury ruled the royalty provision unenforceable yet not materially adverse to ANI, and awarded zero damages on unjust enrichment. ANI plans post-trial motions or appeal. This outcome halts potential 5% royalty revenue stream.
IPO
Employees
Sector
Industry
AMPH
Amphastar Pharmaceuticals, Inc.
24.24+0.06
AMRX
Amneal Pharmaceuticals, Inc.
10.43+0.14
ANIK
Anika Therapeutics Inc.
9.68-0.06
AYTU
Aytu BioPharma, Inc.
2.18+0.02
BIOE
Bio Essence Corp.
0.07+0.00
CPHI
China Pharma Holdings, Inc.
1.78+0.02
ELTP
Elite Pharmaceuticals, Inc.
0.60-0.01
NIKA
NIKA PHARMACEUTICALS INC.
0.30+0.00
NXEN
Nexien BioPharma, Inc.
0.01+0.00
UPC
Universe Pharmaceuticals Inc
4.82-0.29